We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$908M
AUM Growth
+$52.9M
Cap. Flow
+$30.8M
Cap. Flow %
3.39%
Top 10 Hldgs %
29.34%
Holding
100
New
7
Increased
28
Reduced
31
Closed
12

Top Buys

Rank Stock Value
1
HBNC icon
Horizon Bancorp
HBNC
+$17.6M
2
HCA icon
HCA Healthcare
HCA
+$17.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.66M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.58M
5
LLY icon
Eli Lilly
LLY
+$7.22M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24.8M
2
ARRY
Array Biopharma Inc
ARRY
+$14.8M
3
AGN
Allergan plc
AGN
+$13M
4
CI icon
Cigna
CI
+$9.95M
5
WBA
Walgreens Boots Alliance
WBA
+$9.17M

Sector Composition

Rank Sector Weight
1 Healthcare 91.04%
2 Financials 2.97%
3 Industrials 0.36%
4 Technology 0.08%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$121B
$34M 3.74%
185,232
+40,832
+28% +$7.14M
HUM icon
2
Humana
HUM
$43.7B
$27.9M 3.07%
105,000
+28,000
+36% +$7.1M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.9B
$26.7M 2.94%
187,171
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$26.6M 2.93%
203,017
+66,551
+49% +$8.58M
HBNC icon
5
Horizon Bancorp
HBNC
$1.04B
$26.2M 2.88%
+1,087,656
New +$17.6M
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$25.8M 2.84%
48,333
-630
-1% -$316K
UNH icon
7
UnitedHealth
UNH
$376B
$25.6M 2.82%
105,000
-18,400
-15% -$4.43M
ELV icon
8
Elevance Health
ELV
$81.5B
$25.4M 2.8%
90,000
+16,355
+22% +$4.47M
ABMD
9
DELISTED
Abiomed Inc
ABMD
$24.2M 2.67%
92,900
+407
+0.4% +$108K
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$24.1M 2.65%
281,349
+49,800
+22% +$4.26M
NVCR icon
11
NovoCure
NVCR
$1.73B
$23.1M 2.55%
365,899
-88,748
-20% -$4.5M
ABT icon
12
Abbott
ABT
$183B
$21.8M 2.4%
259,552
– –
BDX icon
13
Becton Dickinson
BDX
$45.6B
$20.2M 2.22%
82,000
+5,125
+7% +$1.19M
ESPR
14
DELISTED
Esperion Therapeutics
ESPR
$19.2M 2.11%
412,093
-67,674
-14% -$3.18M
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.7M 2.07%
182,008
+54,915
+43% +$4.28M
CVS icon
16
CVS Health
CVS
$133B
$18.7M 2.06%
343,768
-10,100
-3% -$544K
IOVA icon
17
Iovance Biotherapeutics
IOVA
$1.82B
$18.4M 2.03%
750,700
-128,900
-15% -$1.94M
HCA icon
18
HCA Healthcare
HCA
$87.2B
$18.4M 2.03%
+136,164
New +$17.2M
GKOS icon
19
Glaukos
GKOS
$9.83B
$17.8M 1.96%
235,911
+332
+0.1% +$23.8K
LLY icon
20
Eli Lilly
LLY
$1.02T
$17.7M 1.95%
160,000
+61,305
+62% +$7.22M
BSX icon
21
Boston Scientific
BSX
$69.5B
$16.7M 1.84%
387,908
+20,000
+5% +$769K
MDT icon
22
Medtronic
MDT
$109B
$15.9M 1.75%
162,883
-5,959
-4% -$544K
KYNB
23
Kyntra Bio
KYNB
$27.2M
$15.7M 1.73%
13,898
+6,318
+83% +$6.92M
CNC icon
24
Centene
CNC
$30.7B
$15.5M 1.7%
295,000
+95,000
+48% +$5.13M
BMY icon
25
Bristol-Myers Squibb
BMY
$133B
$15.3M 1.69%
338,386
+108,386
+47% +$5.05M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rhenman & Partners Asset Management held 100 positions worth $908M, up 6.2% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $30.8M of net new capital in Q2 2019, opening 7 new positions and adding to 28 existing holdings. Its largest new stake was Horizon Bancorp: 1,087,656 shares worth $26.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.95M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2019 buy was Horizon Bancorp: 1,087,656 shares worth $26.2M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $9.66M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2019 reduction was Cigna, cutting an estimated $9.95M.
  • Rhenman & Partners Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019, selling an estimated $24.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $908M portfolio in Q2 2019.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 12 in Q2 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 6.2% quarter-over-quarter to $908M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2019, filed 22 Jul 2019.